Meeting
2020 ASCO Virtual Scientific Program
Randomized phase II study of canakinumab (CAN) or pembrolizumab (PEM) as monotherapy or in combination as neoadjuvant therapy in patients (Pts) with surgically resected (Stage IB-IIIA) non-small cell lung cancer (NSCLC): CANOPY-N.
Authors
Tony S. K. Mok
The Chinese University of Hong Kong, Hong Kong, China
Tony S. K. Mok , Pilar Garrido Lopez , Edward S. Kim , Cagatay Arslan , Jean-Louis Pujol , Yuanbo Song , Cecile Blin , Vanessa Rodrik-Outmezguine , Bijoyesh Mookerjee , Vanessa Q. Passos , Jay M. Lee
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT03968419
Citation
J Clin Oncol 38: 2020 (suppl; abstr TPS9626)
DOI
10.1200/JCO.2020.38.15_suppl.TPS9626
Abstract #
TPS9626
Poster Bd #
392
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
A phase 1 first-in-human dose finding/randomized phase 2 study of IMM60 and pembrolizumab (PEM) in advanced melanoma and non–small cell lung cancer (NSCLC; IMP-MEL).
First Author: Nicholas Coupe
Poster
2018 ASCO Annual Meeting
Afatinib in combination with pembrolizumab in patients (pts) with stage IIIB/IV squamous cell carcinoma (SCC) of the lung.
First Author: Benjamin Philip Levy
Poster
2024 ASCO Annual Meeting
Phase 1 study of CTX-471, a novel CD137 agonist antibody, in patients with progressive disease following PD-1/PD-L1 inhibitors in metastatic or locally advanced malignancies.
First Author: Minal A. Barve
Poster
2023 ASCO Annual Meeting
IMPORT-201 (IMP-MEL): A phase 1 first-in-human dose finding/randomized phase 2 study of a novel iNKT agonist IMM60 and pembrolizumab for advanced melanoma and metastatic non-small cell lung cancer (NSCLC).
First Author: Nicholas Coupe